PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
ARCT vs. CNXC
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ARCT and CNXC is 0.25, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

ARCT vs. CNXC - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Arcturus Therapeutics Holdings Inc. (ARCT) and Concentrix Corporation (CNXC). The values are adjusted to include any dividend payments, if applicable.

-40.00%-30.00%-20.00%-10.00%0.00%10.00%20.00%AugustSeptemberOctoberNovemberDecember2025
-25.18%
-21.35%
ARCT
CNXC

Key characteristics

Sharpe Ratio

ARCT:

-0.66

CNXC:

-1.00

Sortino Ratio

ARCT:

-0.73

CNXC:

-1.39

Omega Ratio

ARCT:

0.91

CNXC:

0.81

Calmar Ratio

ARCT:

-0.56

CNXC:

-0.59

Martin Ratio

ARCT:

-1.09

CNXC:

-1.11

Ulcer Index

ARCT:

44.78%

CNXC:

43.43%

Daily Std Dev

ARCT:

74.44%

CNXC:

48.25%

Max Drawdown

ARCT:

-90.09%

CNXC:

-81.19%

Current Drawdown

ARCT:

-86.46%

CNXC:

-74.59%

Fundamentals

Market Cap

ARCT:

$453.44M

CNXC:

$3.23B

EPS

ARCT:

-$2.33

CNXC:

$3.71

Total Revenue (TTM)

ARCT:

$117.39M

CNXC:

$9.62B

Gross Profit (TTM)

ARCT:

$124.76M

CNXC:

$3.09B

EBITDA (TTM)

ARCT:

-$51.84M

CNXC:

$1.15B

Returns By Period

In the year-to-date period, ARCT achieves a -1.36% return, which is significantly lower than CNXC's 16.29% return.


ARCT

YTD

-1.36%

1M

1.39%

6M

-25.20%

1Y

-51.66%

5Y*

N/A

10Y*

N/A

CNXC

YTD

16.29%

1M

20.12%

6M

-21.35%

1Y

-50.82%

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ARCT vs. CNXC — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ARCT
The Risk-Adjusted Performance Rank of ARCT is 1515
Overall Rank
The Sharpe Ratio Rank of ARCT is 1313
Sharpe Ratio Rank
The Sortino Ratio Rank of ARCT is 1515
Sortino Ratio Rank
The Omega Ratio Rank of ARCT is 1616
Omega Ratio Rank
The Calmar Ratio Rank of ARCT is 1414
Calmar Ratio Rank
The Martin Ratio Rank of ARCT is 1919
Martin Ratio Rank

CNXC
The Risk-Adjusted Performance Rank of CNXC is 99
Overall Rank
The Sharpe Ratio Rank of CNXC is 33
Sharpe Ratio Rank
The Sortino Ratio Rank of CNXC is 55
Sortino Ratio Rank
The Omega Ratio Rank of CNXC is 66
Omega Ratio Rank
The Calmar Ratio Rank of CNXC is 1212
Calmar Ratio Rank
The Martin Ratio Rank of CNXC is 1818
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ARCT vs. CNXC - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Arcturus Therapeutics Holdings Inc. (ARCT) and Concentrix Corporation (CNXC). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for ARCT, currently valued at -0.66, compared to the broader market-2.000.002.004.00-0.66-1.00
The chart of Sortino ratio for ARCT, currently valued at -0.73, compared to the broader market-4.00-2.000.002.004.006.00-0.73-1.39
The chart of Omega ratio for ARCT, currently valued at 0.91, compared to the broader market0.501.001.502.000.910.81
The chart of Calmar ratio for ARCT, currently valued at -0.56, compared to the broader market0.002.004.006.00-0.56-0.59
The chart of Martin ratio for ARCT, currently valued at -1.09, compared to the broader market0.0010.0020.0030.00-1.09-1.11
ARCT
CNXC

The current ARCT Sharpe Ratio is -0.66, which is higher than the CNXC Sharpe Ratio of -1.00. The chart below compares the historical Sharpe Ratios of ARCT and CNXC, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.00AugustSeptemberOctoberNovemberDecember2025
-0.66
-1.00
ARCT
CNXC

Dividends

ARCT vs. CNXC - Dividend Comparison

ARCT has not paid dividends to shareholders, while CNXC's dividend yield for the trailing twelve months is around 2.47%.


TTM2024202320222021
ARCT
Arcturus Therapeutics Holdings Inc.
0.00%0.00%0.00%0.00%0.00%
CNXC
Concentrix Corporation
2.47%2.87%1.15%0.77%0.14%

Drawdowns

ARCT vs. CNXC - Drawdown Comparison

The maximum ARCT drawdown since its inception was -90.09%, which is greater than CNXC's maximum drawdown of -81.19%. Use the drawdown chart below to compare losses from any high point for ARCT and CNXC. For additional features, visit the drawdowns tool.


-90.00%-85.00%-80.00%-75.00%-70.00%-65.00%AugustSeptemberOctoberNovemberDecember2025
-86.46%
-74.59%
ARCT
CNXC

Volatility

ARCT vs. CNXC - Volatility Comparison

Arcturus Therapeutics Holdings Inc. (ARCT) has a higher volatility of 19.83% compared to Concentrix Corporation (CNXC) at 9.56%. This indicates that ARCT's price experiences larger fluctuations and is considered to be riskier than CNXC based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%15.00%20.00%25.00%AugustSeptemberOctoberNovemberDecember2025
19.83%
9.56%
ARCT
CNXC

Financials

ARCT vs. CNXC - Financials Comparison

This section allows you to compare key financial metrics between Arcturus Therapeutics Holdings Inc. and Concentrix Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab